Integrative Physician's Perspective
In this case, we see a presentation that is almost pathognomonic for ovarian cancer: such complaints to a primary care practitioner of vague abdominal symptoms and lower abdominal pains that result in a negative test-a colonoscopy-can quite often turn out to be a different cancer. Vague symptoms of this type are a major reason that so many ovarian cancer patients are diagnosed at relatively advanced stages of disease. This reality points out why it is so important that the primary care physician maintain open channels of communication with patients, including those who often attempt self-treatment (a group that contains many of the patients who seek out integrative practitioners). Although no such case has been reported in the literature, one can envision a patient at-tempting to treat the vague abdominal pains of undiagnosed ovarian cancer with a variety of over-thecounter drugs, herbs, supplements, and other approaches, resulting in a delay that can be the difference between an early versus a late (and more ominous) diagnosis.
Medical Oncology
Dr Nathan's first point, that nearly two thirds of ovarian cancer patients experience recurrence of their disease within the first 2 years after surgery, is certainly sobering. This statistic points out the need to view an elevation of CA-125 with considerable suspicion. Because catching a recurrence early may contribute substantially to the outcome of treatment, the practitioner caring for an ovarian cancer patient would be well advised to maintain an especially vigilant observation. The other particularly interesting point Nathan points out is the import of the patient's relatively long disease-free interval. Because patients who have recurrences more than 6 months after the initial treatment have a good possibility to respond to platinum-based therapies, it does seem that a platinum-taxane therapy would be a good starting point with this patient.
Radiation Oncology
Dr Bugno's opening statement reminds us all of the importance of not overlooking any discipline when developing a comprehensive plan of care for a cancer patient. Even if a particular modality is commonly believed to have little relevance for a patient's care, there may be value in consulting a specialist with a different perspective. Consistent with Bugno's interesting perspectives on this case are his mention of different treatment practices in the United States and Europe and his mention of the potential benefits of amifostine. Although the evidence for the efficacy of amifostine to date is still limited, I am quite familiar with and supportive of the benefits in reducing the toxicity of radiation and chemotherapy patients in clinical practice, especially with patients undergoing platinum or taxane-based regimens. Bugno also raises the possibility that a reexamination of the patient may be in order in light of the findings of elevated CA-125 with limited findings on CT scan; the suggestion of fusion PET scanning, an emerging technology with the ability to detect small foci of disease (< 1 cm), may add critical diagnostic information when weighing options of care.
Bugno recognizes the support concerns of this patient: she is unmarried, has been under job stress, and apparently has few family members living in this country. Such broader integrative thinking has certainly not been the norm among those practicing in such a highly technological field such as radiation oncology. Such notable care certainly is a sign of a shift in the medical guard.
Naturopathy
Dr Labriola first mentions the possibility that the apparent recurrence might not be a recurrence at all, but rather residual disease, a metastatic focus that was present at the time of the original surgery but was missed in the surgical procedure. This would imply that the patient actually did not respond to the initial chemotherapy, since a response would presumably have resulted in disappearance of the lymph node disease. Lack of response to the initial carboplatinpaclitaxel regimen would indicate that another drug would be a better choice. Even a biopsy, however, would be unlikely to show whether it was residual disease or a recurrence. Unfortunately, while a valuable insight, it is not possible to verify or act on this at this time.
Labriola mentions the use of St. John's wort after surgery. St. John's wort is used both for depression and, externally, in the form of oil, for wound care. I would urge readers to review the article published in the first issue of this journal concerning the interactions of herbs and various chemotherapy and other drugs used in cancer treatment. Because St. John's wort is an herb associated with specific drug interactions, it would be wise to evaluate its use after surgery in light of other medications in use at that time.
The recognition by naturopathic practitioners that no 2 patients have the exact same disease is commendable. I am well aware, as is Labriola, that much of conventional medicine and research addressing drug therapies is based on a generic model of delivery of identical therapy to patients with the same conventional diagnosis. This present model loses sight of the overarching importance of care individualized to each patient.
Nutrition
Lagomarcino begins her analysis with an extensive survey of the data on nutritional risks for ovarian cancer. While these data are not specifically addressed to the therapeutic situation, the findings forge a compelling link between nutritional background and disease risk. I respect Lagomarcino for not making the leap from nutritional modification of disease risk to nutritional modification of disease prognosis. However, it is clear to me that the periods conventionally designated as precancerous and cancer in fact overlap substantially: a patient diagnosed with advanced disease has presumably had a rather lengthy period of undetected disease development in which they would have been labeled as not having cancer, but only a risk level for cancer. I would therefore be bold enough in clinical practice to assert that the data presented by Lagomarcino for risk reduction are indeed relevant during the period of disease treatment as well.
The study of Willett et al mentioned by Lagomarcino found no significant association of ovarian cancer risk and dietary fat. It should be borne in mind that during the time data were collected for this study of nurses, there were a relatively small number of subjects following truly low-fat diets. And we feel that it is also reasonable to suppose that many of these were following such diets (eg, Weight Watchers ® ) for purposes of weight reduction. These patients would also, then, be those who already had problems with obesity, which may have predisposed them to other types of nutritional problems. This could have explained the lack of a protective effect for low-fat diets in this study. Low-fat diets followed during the period of data collection may also have had little resemblance to the diets prescribed by most integrative practitioners today: they may have been lacking in unrefined grains and may have accepted or advocated amounts and types of sugars that today's integrative practitioners would find objectionable.
The nutritional recommendations offered in this piece are very reasonable. I was also happy to see the suggestions for more detailed laboratory workups, especially the recommendation for oxidative stress testing.
Mind-Spirit Therapy
Penny Block and I have been working together for more than 2 decades on the development of our model of integrative care, so an impartial discussion of her contribution to this tumor board is impossible. I would note that one of the hopes of our program of mind-spirit therapy is that by addressing the emotional dimensions of cancer and its treatment, we may assist patients in developing a strong commitment to active participation in their program of integrative care. Cunningham's research in this area examined cancer patients who undertook programs involving a group psychotherapy model which included basic coping skills, relaxation, thought monitoring, mental imaging, goal setting, and communication skills. 1 He found that those who approached the program with wholehearted involvement appeared to have survived longer than those who had moderate or low involvement. Some of factors that appeared to inhibit involvement were inhibited self-expressiveness with consequent withdrawal from emotional situations, and blocking by personal issues including self-esteem and helplessness.
Massage Therapy
This piece, from faculty members of the Chicago School of Massage Therapy, is most impressive in both its scope and its sensitivity. I was glad to see that Alvarado and Chamness recognize the potential concerns with massage therapy, even though these are still theoretical and not confirmed by clinical studies. I would add to the possible concerns the point that direct manipulation of the tumor itself may cause secretion of growth signals that promote further tumor growth.
However, these authors do recognize what I have found clinically: massage does have great therapeutic benefits for cancer patients. The findings on massage therapy resulting in lower cortisol levels, and the recommendations of the National Cancer Institute of massage therapy for nausea, vomiting, and diarrhea of chemotherapy, are impressive indications of these benefits.
My only caution about these recommendations is the mention of massage therapy 2 to 3 times per week. It is our experience that for patients who are in a weakened condition due to chemotherapy or radiation treatment, massage may actually be somewhat fatiguing in spite of its benefits. It is possible that for such patients, massage would better be limited to once a week. Otherwise, I found this to be a most interesting presentation in an area of great relevance for the humane care of cancer patients.
